Decitabine + Venetoclax + FHD-286
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Trial Timeline
Feb 3, 2026 → Feb 1, 2030
NCT ID
NCT07283094About Decitabine + Venetoclax + FHD-286
Decitabine + Venetoclax + FHD-286 is a phase 1 stage product being developed by Foghorn Therapeutics for Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07283094. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07283094 | Phase 1 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukemia